Search

Aims: The prevalence and associations of overweight and obesity in Canadian adult people living with type 1 diabetes (PWT1D) are poorly documented. In a cohort of PWT1D patients, this study assesses (i) overweight and obesity frequencies and associated PWT1D clinicodemographic characteristics, (ii) diabetes characteristics, and (iii) the use of noninsulin adjunctive agents. Materials and Methods: Cross‐sectional analysis of self‐reported data from the BETTER registry: 1091 adult PWT1D (aged 44.4 ± 15.0 years; 32% HbA1c<7% [53 mmol/mol]) classified by BMI classes: underweight combined with normal weight, overweight, or obesity. Bivariate analyses were used to identify associations between BMI classes, diabetes characteristics, complications, and treatments. Results: Overweight and obesity affected 34.6% and 19.8% of participants. Compared to underweight + normal weight, PWT1D with overweight/obesity was associated with male sex, higher age, lower education level, longer diabetes duration, and higher total insulin doses and use of cardiorenal therapies (all p < 0.001). Compared to other PWT1D, those living with obesity reported higher HbA1c (p < 0.05), less frequent hypoglycemia (p < 0.05), more cardiovascular diseases (p < 0.003), retinopathy, neuropathy, depression treatment as well as noninsulin adjunctive agent use (all p < 0.001). Logistic regression showed that living with overweight/obesity was associated with male sex, being treated for cardiorenal therapies, depression, diabetes duration, and total daily insulin doses. Conclusions: Overweight or obesity affects over half of adult PWT1D in the Canadian BETTER registry and is associated with higher HbA1c levels, higher total daily insulin doses, more chronic diabetes complications and noninsulin adjunctive agent use, a worse cardiometabolic profile, and lower hypoglycemia frequency. [ABSTRACT FROM AUTHOR]

The article discusses research by Maha Lebbar, Zoé Henry, and Charles Thivolet, reported in the Diabetes Care issue focusing on topics such as the comparison of glucose control and patient-reported outcomes after initiation of advanced hybrid closed-loop (AHCL) insulin delivery systems (Medtronic SmartGuard 780G and Tandem T-Slim Control-IQ), differences in continuous glucose monitoring outcomes between AHCL systems, and the impact of age on glucose efficacy.

3 Wu Z, Yardley JE, Messier V, Legault L, Grou C, Rabasa-Lhoret R. Comparison of nocturnal glucose after exercise among dual-hormone, single-hormone algorithm-assisted insulin delivery system and usual care in adults and adolescents living with type 1 diabetes: a pooled analysis [published online ahead of print June 24, 2022]. Keywords: automated insulin delivery system; children and adolescents; glucagon; nocturnal glucose; type 1 diabetes EN automated insulin delivery system children and adolescents glucagon nocturnal glucose type 1 diabetes 310 313 4 12/13/22 20230101 NES 230101 BACKGROUND Automated insulin delivery (AID) systems combine insulin pump(s), continuous glucose monitoring (CGM) and a dosing algorithm automatically delivering insulin (single-hormone AID [SH-AID]) or insulin + glucagon (dual-hormone AID [DH-AID]). Histogram (mean) of glucagon delivery profile during dual-hormone automated insulin delivery intervention in children and adolescents with type 1 diabetes (N = 123 nights) Footnotes 1 Zekai Wu is the senior author. Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: A pooled analysis. [Extracted from the article]

The cover image is based on the Research Letter I Comparing dual-hormone and single-hormone automated insulin delivery systems on nocturnal glucose management among children and adolescents with type 1 diabetes: A pooled analysis i by Zekai Wu MD et al., https://doi.org/10.1111/dom.14850. [Extracted from the article]